Phase 1 N=26 Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
Alcohol Dependence
Primary: Craving for Alcohol in Alcohol Dependence With Citalopram Compared to Placebo — 21; 30.4; 10.8; 10.6 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=459 This is a Post Approval Study of Coaptite® in the Treatment of Female Urinary Incontinence
Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency
Primary: Incontinence Status as Assessed by Stamey Grade Score — 2.5; 1.6; 1.5; 1.6 score on a scale
Phase 1 N=58 An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors
Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of Eribulin-LF — 1.4; 1.5 mg/m^2
Phase 2 N=12 An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Number of Participants With Adverse Events as Assessed by CTCAE Version 4.03 — 10; 10; 11; 11 participants
Phase 2 N=305 A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Absolute Change From Baseline in 6-minute Walking Distance (6MWD) After 20 Weeks of Treatment — 329; 306; 300; 328 meter — p=0.5183
Phase 1 N=5 Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma
Neuroblastoma
Primary: Number of Participants With Immediate and Short Term Toxicity of Infusion Over 8 Weeks — 0; 0; 3 Participants
Phase 3 N=101 Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.
Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Primary: Receiver Operating Characteristic (ROC) Analysis on Peak GH (Growth Hormon) Concentrations — 2.36; 17.71 ng/mL
Phase 3 N=495 A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.
Bipolar I Disorder
Primary: Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR) — 352; 169 Participants
N/A N=213 Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms
Brain Aneurysm
Primary: mITT Primary Effectiveness Endpoint. Based on Subjects With 100% Occlusion of the Aneurysm Without Clinically Significant Stenosis of the Parent Artery, and Without Any…
N/A N=10,805 Manicaland Cash Transfer Trial for Children in Zimbabwe
Vaccination · Education · Birth Registration
Primary: Proportion of Children Under 5 Years in Vulnerable Households That Have a Birth Certificate — 252; 255; 163 Participants
N/A N=9 Exercise as an Adjuvant to Aphasia Therapy
Aphasia
Primary: Change in Picture Naming Abilities as Measured by Tau U Effect Size Weighted Means — 0.83; 0.75; 0.88; 0.77 Tau U effect size weighted mean — p=< 0.001
Phase 4 N=363 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)
Macular Degeneration
Primary: Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to Month 12 — -4.8; -0.9 ETDRS Letters
N/A N=8 A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations
Sunscreening Agents
Primary: Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values — 33.1; 35.2; 35.2; 45.2 Ratio
Phase 3 N=46 YH1 in Poorly Controlled Type 2 Diabetes
Type 2 Diabetes
Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change
N/A N=188 Interventions in Nutrition Education and Skills
Obesity
Primary: Change in BLOCK Fruit/Vegetable/Fiber Screener From Baseline at 12 Months — 16.6; 15.9; 18.0; 16.3 units on a scale — p=0.26